fulvestrant has been researched along with byl719 in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (22.58) | 24.3611 |
| 2020's | 24 (77.42) | 2.80 |
| Authors | Studies |
|---|---|
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Cheung, P; Kakit, C; Kiess, N; Parsons, R; Pegno, S; Poulikakos, PI; Schmidt, H; Stratikopoulos, EE; Szabolcs, M; Wu, X | 1 |
| Arteaga, C; Floris, G; Hoste, G; Jongen, L; Matton, T; Menten, J; Neven, P; Punie, K; Slembrouck, L; Vanden Bempt, I; Vander Borght, S; Wildiers, H | 1 |
| Baselga, J; Blumenstein, L; Bootle, D; Burris, HA; Demanse, D; Gil-Martin, M; Huang, A; Janku, F; Juric, D; Mayer, IA; Middleton, MR; Quadt, C; Rodón, J; Rugo, HS; Schuler, M; Schumacher, K; Seggewiss-Bernhardt, R | 1 |
| André, F; Campone, M; Ciruelos, E; Conte, P; Hirawat, S; Inoue, K; Iwata, H; Juric, D; Kaufman, B; Loibl, S; Longin, AS; Lu, YS; Mayer, IA; Mills, D; Pápai, Z; Rubovszky, G; Rugo, HS; Takahashi, M; Wilke, C; Yamashita, T | 1 |
| Stirrups, R | 1 |
| Markham, A | 1 |
| Melegari, E; Palleschi, M; Rocca, A | 1 |
| Adler, B; Bass, IR; Gallagher, EJ; Ryncarz, A; Tiersten, A; Trlica, K | 1 |
| André, F; Campone, M; Cerda, H; Ciruelos, EM; Conte, P; Gaudenzi, F; Iwata, H; Jurado, JC; Juric, D; Loibl, S; Lteif, A; Mayer, I; Miller, M; Mills, D; Rugo, HS; Stemmer, SM; Toledano, I; Wilke, C; Yamashita, T | 1 |
| Copur, MS | 1 |
| Abdelhady, AM; Bachelot, T; Calvo, E; Fasolo, A; Forero-Torres, A; Hamilton, E; Im, YH; Lee, SC; Lu, YS; Maur, M; Nardi, L; Ruan, S; Stammberger, U; Tiedt, R; Tolaney, SM | 1 |
| Corbaux, P; Sabatier, R | 1 |
| Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Chatterjee, DK; Chen, W; Chen, X; Fan, J; Fernandes, LL; Gao, JJ; Geiser, G; Ghosh, S; Goldberg, KB; Gong, Y; Jiang, X; King-Kallimanis, BL; Kluetz, PG; Li, E; Narayan, P; Pathak, A; Pazdur, R; Philip, R; Prowell, TM; Qiu, J; Reyes Turcu, F; Rhieu, SY; Ricks, TK; Seidman, J; Song, P; Tang, S; Theoret, MR; Wang, X; Windsor, K; Yu, J; Zhang, X | 1 |
| André, F; Campone, M; Ciruelos, EM; Conte, PF; Ghaznawi, F; Inoue, K; Iwata, H; Juric, D; Kaper, M; Kaufman, B; Loibl, S; Lu, YS; Mayer, IA; Miller, M; Mills, D; Pápai, Z; Rubovszky, G; Rugo, HS; Takahashi, M; Yamashita, T | 1 |
| Foukakis, T; Matikas, A | 1 |
| Arce, C; Bachelot, T; Chia, S; Ciruelos, E; Drullinsky, P; Hsu, WC; Juric, D; Kanakamedala, H; Lerebours, F; Neven, P; Park, YH; Prat, A; Rugo, HS; Ruiz-Borrego, M; Shen, YM; Sophos, N; Turner, N; Turner, S; Zarate, JP | 1 |
| Chandiwana, D; Chia, S; Hsu, WC; Kanakamedala, H; Park, J; Ridolfi, A; Rugo, HS; Turner, S; Yu, CL; Zarate, JP | 1 |
| Bièche, I; Chateau-Joubert, S; Dahmani, A; De Plater, L; El Botty, R; Jacquemetton, J; Kassem, L; Le Romancer, M; Marangoni, E; Montaudon, E; Morisset, L; Poulard, C; Sourd, L; Trédan, O; Treilleux, I; Vacher, S | 1 |
| Albert, R; Alcon, C; Baselga, J; Gómez Tejeda Zañudo, J; Johnson, GN; Kowalski, K; Letai, A; Mao, P; Montero, J; Scaltriti, M; Wagle, N; Xu, G | 1 |
| Albert, R; Alcon, C; Gómez Tejeda Zañudo, J; Letai, A; Montero, J; Samitier, J; Scaltriti, M; Wagle, N | 1 |
| Jacobson, A | 1 |
| Armgardt, E; Miller, J; Svoboda, A | 1 |
| Adam, V; Bedard, PL; Carrasco, E; Criscitiello, C; Di Leo, A; Pérez-Fidalgo, JA; Regan, MM; Ribi, K | 1 |
| Fisher, V; Graf, RP; Lee, JK; Madison, RW; Oxnard, GR; Raskina, K; Rugo, HS; Schrock, AB; Sivakumar, S; Sokol, ES; Tukachinsky, H | 1 |
| Burnette, SE; Force, J; Lee, HJ; Moore, HN; Poehlein, E; Westbrook, K | 1 |
| Akla, S; Bailleux, C; Bello Roufai, D; Benderra, MA; Bertho, M; Bertucci, A; Bidard, FC; Blonz, C; Cottu, P; De La Motte Rouge, T; Delaloge, S; Desmoulins, I; Gligorov, J; Gonçalves, A; Grenier, J; Lerebours, F; Loirat, D; Pierga, JY; Renaud, E; Renouf, B; Robert, L; Saghatchian, M; Simon, H; Tharin, Z | 1 |
| Kaderbhaï, CG; Royer, B; Schmitt, A | 1 |
| Behrendt, CE; Ge, X; Lavasani, S; Mortimer, J; Patel, N; Samoa, R; Sedrak, M; Stewart, D; Waisman, J; Yost, SE; Yuan, Y | 1 |
| Cai, J; Hu, C; Lin, H; Liu, J; Sun, H; Wei, X; Wu, W | 1 |
3 review(s) available for fulvestrant and byl719
| Article | Year |
|---|---|
Alpelisib: First Global Approval.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Approval; Female; Fulvestrant; Humans; Male; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Thiazoles; United States; United States Food and Drug Administration | 2019 |
Alpelisib to treat breast cancer.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Fulvestrant; Humans; Mutation; Receptor, ErbB-2; Thiazoles | 2020 |
Pharmacokinetics and Pharmacodynamic of Alpelisib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Thiazoles | 2023 |
9 trial(s) available for fulvestrant and byl719
| Article | Year |
|---|---|
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Maximum Tolerated Dose; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Receptors, Estrogen; Thiazoles; Time Factors | 2019 |
Alpelisib for
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Diarrhea; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2019 |
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Male; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2020 |
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Drug Approval; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Patient Reported Outcome Measures; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2021 |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Male; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2021 |
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Topics: Adolescent; Adult; Aged; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2021 |
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2021 |
Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Receptor, ErbB-2; Thiazoles | 2021 |
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase III as Topic; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles; Trastuzumab | 2022 |
19 other study(ies) available for fulvestrant and byl719
| Article | Year |
|---|---|
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Mouse ER+/PIK3CA
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cocarcinogenesis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knock-In Techniques; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Mutation, Missense; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neuropeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides; Thiazoles | 2019 |
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Middle Aged; Mutation; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2018 |
Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Combinations; Fulvestrant; Humans; Mutation; Thiazoles | 2019 |
Precision medicine: PI3K targeting in advanced breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Mutation; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; PTEN Phosphohydrolase; Thiazoles | 2019 |
Novel breast cancer treatment leads to hyperglycaemia.
Topics: Aged; Antineoplastic Agents, Hormonal; Blood Glucose; Blood Glucose Self-Monitoring; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Hyperglycemia; Monitoring, Ambulatory; Phosphoinositide-3 Kinase Inhibitors; Prediabetic State; Thiazoles | 2020 |
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Purines; Receptors, Estrogen; Thiazoles | 2021 |
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Male; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2020 |
SOLAR1s: alpelisib returns to earth?
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Fulvestrant; Humans; Thiazoles | 2021 |
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fulvestrant; Genomics; Humans; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Proto-Oncogene Proteins pp60(c-src); Receptors, Estrogen; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2021 |
Cell Line-Specific Network Models of ER
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Computer Simulation; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; HEK293 Cells; Humans; MCF-7 Cells; Models, Theoretical; Myeloid Cell Leukemia Sequence 1 Protein; Receptors, Estrogen; Retinoblastoma Binding Proteins; Signal Transduction; Thiazoles; Ubiquitin-Protein Ligases | 2021 |
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Protein Isoforms; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Thiophenes | 2021 |
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Letrozole; Thiazoles | 2022 |
The efficacy and safety of alpelisib in breast cancer: A real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Retrospective Studies | 2022 |
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.
Topics: Biology; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Receptor, ErbB-2 | 2023 |
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; EGF Family of Proteins; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Risk Factors | 2023 |
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Middle Aged; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2 | 2023 |
Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Prediabetic State; Receptor, ErbB-2; Retrospective Studies | 2023 |
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Mutation; Receptor, ErbB-2 | 2023 |